Drug Trial Radar · NCT03801889
SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias
Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 2020
Primary completion
Sep 2022
Study completion Jan 2023
Sponsor
- Lead sponsor
- Abfero Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.
Conditions
- Iron Overload
- Beta-Thalassemia
Interventions
SP-420Drug
Self-administered by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of treatment-emergent Adverse Events (AEs)Time frame: Week 24
- The incidence of treatment-emergent Adverse Events (AEs)Time frame: Week 52
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
University of Toronto- University Health Network
Toronto, Canada
American University of Beirut Medical Center
Beirut, Lebanon
Siriraj Hospital
Bangkok, Thailand
Ege University Hospital
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.